Guardant Health

General Information
Business:

We are a leading precision oncology company focused on helping conquer cancer globally through use of our proprietary blood tests, vast data sets and advanced analytics. We believe that the key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which we intend to enable by a routine blood draw, or liquid biopsy. Our Guardant Health Oncology Platform is designed to leverage our capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of our goal to manage cancer across all stages of the disease, we have launched our liquid biopsy tests, Guardant360 and GuardantOMNI, for advanced stage cancer, which fuel our programs developing tests for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Guardant360, which we launched in 2014 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 National Comprehensive Cancer Network, or NCCN, Centers, and we believe it is the world’s market leading comprehensive liquid biopsy test based on public disclosure of the number of comprehensive liquid biopsy tests sold in 2017. Precision oncology, as it is practiced today, is primarily focused on matching cancer patients to personalized treatments based on the underlying molecular profile of their tumors

Industry: MEDICAL LABORATORIES
Employees: 348
Founded: 2011
Contact Information
Address 505 Penobscot Drive, Redwood City, CA 94063, US
Phone Number (855) 698-8887
Web Address http://www.guardanthealth.com
View Prospectus: Guardant Health
Financial Information
Market Cap $1336.9mil
Revenues $67.2 mil (last 12 months)
Net Income $-83.8 mil (last 12 months)
IPO Profile
Symbol GH
Exchange NASDAQ
Shares (millions): 12.5
Price range $15.00 - $17.00
Est. $ Volume $200.0 mil
Manager / Joint Managers J.P. Morgan/ BofA Merrill Lynch
CO-Managers Cowen/ Leerink Partners/ William Blair
Expected To Trade: 10/1/2018
Day: Week of
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change